Ipsen Sa Adr Company Profile (OTCMKTS:IPSEY)

About Ipsen Sa Adr (OTCMKTS:IPSEY)

Industry, Sector and Symbol:

Sector: Medical
Industry: N/A
Sub-Industry: N/A
Symbol: OTCMKTS:IPSEY
CUSIP: N/A
Web: www.ipsen.com

Capitalization:

Market Cap: $10.68 billion
Outstanding Shares: 329,748,000

Average Prices:

50 Day Moving Avg: $33.44
200 Day Moving Avg: $26.79
52 Week Range: $15.22 - $35.71

P/E:

Trailing P/E Ratio: 41.34
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $1.92 billion
Price / Sales: 5.56
Book Value: $4.73 per share
Price / Book: 6.85

Profitability:

EBIDTA: $444.08 million

Debt:

Current Ratio: 1.87%
Quick Ratio: 1.67%

Misc:

Average Volume: 967 shs.

Frequently Asked Questions for Ipsen Sa Adr (OTCMKTS:IPSEY)

What is Ipsen Sa Adr's stock symbol?

Ipsen Sa Adr trades on the OTCMKTS under the ticker symbol "IPSEY."

How often does Ipsen Sa Adr pay dividends? What is the dividend yield for Ipsen Sa Adr?

Ipsen Sa Adr declared a None dividend on Friday, July 7th. Stockholders of record on Monday, June 12th will be given a dividend of $0.175 per share on Tuesday, July 11th. The ex-dividend date is Thursday, June 8th. View Ipsen Sa Adr's Dividend History.

Who are some of Ipsen Sa Adr's key competitors?

Some companies that are related to Ipsen Sa Adr include Cerner Corporation (CERN), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Quintiles Transitional Holdings (Q), Laboratory Corporation of America Holdings (LH), Smith & Nephew SNATS (SNN), Eisai Co., Ltd (ESALY), BioMarin Pharmaceutical (BMRN), Quest Diagnostics Incorporated (DGX), Henry Schein (HSIC), IDEXX Laboratories (IDXX), DENTSPLY SIRONA (XRAY), Centene Corporation (CNC), Genmab A/S (GNMSF), Lonza Group Ag (LZAGY), Align Technology (ALGN), DaVita HealthCare Partners (DVA) and Olympus Corp. (OCPNY).

How do I buy Ipsen Sa Adr stock?

Shares of Ipsen Sa Adr can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ipsen Sa Adr's stock price today?

One share of Ipsen Sa Adr stock can currently be purchased for approximately $32.39.

MarketBeat Community Rating for Ipsen Sa Adr (OTCMKTS IPSEY)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		45 (Vote Outperform)
Underperform Votes:		48 (Vote Underperform)
Total Votes:		93

MarketBeat's community ratings are surveys of what our community members think about Ipsen Sa Adr and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Ipsen Sa Adr (OTCMKTS:IPSEY) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Ipsen Sa Adr (OTCMKTS:IPSEY)

Show:

Date	Firm	Action	Rating
7/7/2016	J P Morgan Chase & Co	Downgrade	Overweight -> Neutral
5/9/2016	Morgan Stanley	Upgrade	Equal Weight -> Overweight
4/26/2016	Jefferies Group LLC	Upgrade	Hold -> Buy
3/8/2016	Barclays PLC	Downgrade	Overweight -> Equal Weight
2/18/2016	Societe Generale	Initiated Coverage	Buy

(Data available from 7/27/2015 forward)

Earnings History for Ipsen Sa Adr (OTCMKTS:IPSEY)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Ipsen Sa Adr (OTCMKTS:IPSEY)

No earnings estimates for this company have been tracked by MarketBeat.com

Current Dividend Information for Ipsen Sa Adr (OTCMKTS:IPSEY)

Most Recent Dividend:	7/11/2017
Annual Dividend:	$0.17
Dividend Yield:	0.52%
Payout Ratio:

Dividend Payments by Quarter for Ipsen Sa Adr (OTCMKTS:IPSEY)

Dividend History by Quarter for Ipsen Sa Adr (OTCMKTS IPSEY)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/7/2017	None	$0.18		6/8/2017	6/12/2017	7/11/2017

(Data available from 1/1/2013 forward)

Insider Trading History for Ipsen Sa Adr (OTCMKTS:IPSEY)
No insider trades for this company have been tracked by MarketBeat.com

Headline Trends for Ipsen Sa Adr (OTCMKTS:IPSEY) Latest Headlines for Ipsen Sa Adr (OTCMKTS:IPSEY)

Source:

Date	Headline
	Ipsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017 finance.yahoo.com - July 27 at 1:17 AM
	Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy finance.yahoo.com - July 22 at 1:58 AM
	Ipsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New Indication for the Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors finance.yahoo.com - July 3 at 7:06 AM
	Ipsen Announces Co-Promotion Agreement With Saol Therapeutics To Promote Dysport® (abobotulinumtoxinA) in the United States finance.yahoo.com - June 30 at 8:05 PM
	Ipsen Sa Adr (IPSEY) Downgraded by Zacks Investment Research to Hold www.americanbankingnews.com - June 27 at 11:28 PM
	Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma finance.yahoo.com - June 19 at 4:59 PM
	Ipsen Biopharmaceuticals Announces FDA Approval of Dysport www.streetinsider.com - June 17 at 11:29 PM
	Ipsen Sa Adr (IPSEY) Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - June 17 at 12:32 AM
	Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults finance.yahoo.com - June 16 at 6:50 PM
	Ipsen initiates share buy-back program to cover its free performance share allocation plan finance.yahoo.com - June 8 at 6:25 AM
	Combined Shareholders’ Meeting of IPSEN S.A. Held on 7 June 2017 finance.yahoo.com - June 7 at 5:33 PM
	Ipsen Announces New Data to Be Presented at ASCO in Line with Its Continued Commitment to Oncology Research finance.yahoo.com - June 1 at 3:23 PM
	Ipsen Completes Acquisition of Select Consumer Healthcare Products from Sanofi finance.yahoo.com - May 12 at 1:46 PM
	Ipsen Presents Its New Strategy and Improved 2020 Financial Targets finance.yahoo.com - May 12 at 1:46 PM
	Ipsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer finance.yahoo.com - April 14 at 9:24 AM
	Midcap Biopharma Stocks Pick Up In The First Quarter seekingalpha.com - April 7 at 5:51 PM
	Ipsen SA :IPSEY-US: Earnings Analysis: For the six months ended December 31, 2016 : April 3, 2017 us.rd.yahoo.com - April 4 at 4:12 AM
	Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals uk.finance.yahoo.com - April 3 at 5:16 PM
	IPSEN (IPSEY) Raised to "Strong-Buy" at Zacks Investment Research www.americanbankingnews.com - April 3 at 8:02 AM
	Zacks Investment Research Upgrades IPSEN (IPSEY) to "Strong-Buy" www.americanbankingnews.com - March 29 at 1:00 AM
	The Ipsen Group Publishes Its 2016 Registration Document www.businesswire.com - March 28 at 5:34 PM
	UCB Needs Clinical Success To Drive Upside seekingalpha.com - March 21 at 5:55 PM
	Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment … finance.yahoo.com - March 14 at 10:12 PM
	Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Patients with Cervical Dystonia and Adult Upper Limb Spasticity us.rd.yahoo.com - March 14 at 11:47 AM
	Ipsen announces MHRA1 approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer uk.finance.yahoo.com - March 13 at 10:50 AM
	Ipsen Announces Data Presentations of Lanreotide (Somatuline® Autogel®), Telotristat Ethyl and the Investigational Compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 Conference uk.finance.yahoo.com - March 9 at 7:19 AM
	Ipsen Appoints Benoit Hennion as Executive Vice President and President, Primary Care uk.finance.yahoo.com - March 2 at 3:28 PM
	UPDATE 1-FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug finance.yahoo.com - February 28 at 6:06 PM
	Ipsen's (IPSEY) CEO David Meek on Q4 2016 Results - Earnings Call Transcript seekingalpha.com - February 25 at 12:15 AM
	Ipsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017 uk.finance.yahoo.com - February 23 at 4:14 AM
	Drugmaker Ipsen to buy some products from Sanofi for 83 million euros us.rd.yahoo.com - February 13 at 11:07 AM
	3:27 am Ipsen S.A. to acquire 5 of Sanofi's (SNY) Consumer Healthcare Products for EUR83 mln us.rd.yahoo.com - February 13 at 11:07 AM
	Is Merrimack Pharmaceuticals Worth Stashing in Portfolios? www.fool.com - February 12 at 5:49 PM
	Ipsen Biopharmaceuticals, Inc. Announces Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the Association of Academic Physiatrists finance.yahoo.com - February 9 at 6:54 PM
	Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma uk.finance.yahoo.com - January 31 at 4:41 AM
	Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises uk.finance.yahoo.com - January 20 at 5:49 AM
	Ipsen to acquire oncology assets from Merrimack seekingalpha.com - January 9 at 4:45 PM
	Merrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen www.thestreet.com - January 9 at 4:45 PM
	Merrimack Pharma to Sell Cancer Drugs for $1B www.investopedia.com - January 9 at 4:45 PM
	Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus us.rd.yahoo.com - January 8 at 10:43 PM
	Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals us.rd.yahoo.com - January 8 at 10:43 PM
	France's Ipsen to buy some Merrimack assets for up to $1 bln us.rd.yahoo.com - January 8 at 10:43 PM
	France's Ipsen to buy some Merrimack assets for up to $1 billion finance.yahoo.com - January 8 at 10:43 PM
	Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada au.finance.yahoo.com - December 21 at 8:42 AM
	Ipsen Announces Its Corporate Agenda for 2017 uk.finance.yahoo.com - December 13 at 10:16 AM
	Claude Bertrand to Step Down as Executive Vice President, R&D, Chief Scientific Officer of Ipsen uk.finance.yahoo.com - December 12 at 10:50 AM
	IPSEN webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference finance.yahoo.com - November 21 at 10:48 AM
	IPSEN to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 16th, 2016 finance.yahoo.com - November 10 at 5:09 PM
	Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society finance.yahoo.com - October 26 at 5:44 PM
	Ipsen Reports 12.2%1 Sales Growth for the Third Quarter of 2016 and Raises Full Year Guidance uk.finance.yahoo.com - October 26 at 8:53 AM